EDMONTON – BioMS Medical Corp. announced on Thursday that the University of Alberta has received additional patents for the company’s synthetic peptide therapeutic, MBP8298, for the treatment of multiple sclerosis (MS). BioMS Medical licenses these patents on an exclusive worldwide basis from the University of Alberta.
According to a press release by the company, the patent entitled “Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient” has been granted in the United States and addresses methods of predicting efficacy of certain courses of treatment for MS patients.
“We are pleased about our recent patent protection in the United States. Protection of the company’s intellectual property, in the United States and throughout the world, represents a key aspect of our commercial development. It also provides a view into the excellent scientific and clinical development supporting this important MS drug,” said the President and CEO of BioMS Medical Kevin Giese.
BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical’s lead technology, MBP8298, is for the treatment of multiple sclerosis and is currently in a pivotal phase II/III clinical trial across Canada and Europe.
